AI tools increasingly occupy a regulatory gray area in healthcare. For clinicians to assess whether they are trustworthy, they need transparency on how they work, said panelists at CES.
The newly established planning board is made up of experts representing patients, clinicians, academic researchers, the medical device industry and others, and is supported in its work by the Duke-Margolis Center for Health Policy.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.